#Tuberculosis: We conducted the first within-trial cost-utility analysis of 6-month BPaL-based regimens (bedaquiline, pretomanid, and linezolid) for rifampin-resistant #TB.

More about our findings below ⬇️ #IDSky #AidSky #MedSky

Comments